|Articles|July 1, 1999

Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
Volume 5
Issue 10 Suppl

Selected Abstracts

Download PDF: Selected Abstracts

Articles in this issue

almost 27 years ago

Article

Participating Faculty

almost 27 years ago

Article

Introduction

almost 27 years ago

Article

The Impact of Schizophrenic Patient Functionality on Service Utilization and Cost

almost 27 years ago

Article

Evaluation of Outcomes for Atypical Antipsychotic Therapy and Psychosocial Rehabilitation in a Community Mental Health Center

almost 27 years ago

Article

Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

almost 27 years ago

Article

Assessment of Quality-of-Life Outcomes in Schizophrenic Patients

almost 27 years ago

Article

The Emerging Role of Psychiatric Pharmacists

almost 27 years ago

Article

CME/CE Quiz

almost 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Zanubrutinib Tops Rivals in Real-World CLL Survival Study